Company news
Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) news
Kiora Pharmaceuticals, Inc. news releases on 6ix. Latest, Jun 15, 2023: Kiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing…
Press releases — page 2
Kiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201
June 14, 2023
Kiora Pharmaceuticals Announces Closing of $6.3 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
June 5, 2023
Kiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public Offering
June 1, 2023
Kiora Pharmaceuticals Reports First Quarter Results; Positive Clinical Data Driving Significant Progress Advancing Pipeline of Eye Disease Treatments
May 8, 2023
Inherited Retinal Disease Expert, Mark Pennesi, M.D., Ph.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board
April 20, 2023
Kiora Pharmaceuticals Initiates Phase 2 Trial of KIO-101 for the Treatment of Ocular Presentation of Autoimmune Diseases
April 16, 2023
Kiora Announces the Acceptance of Late-Breaking Abstract on Phase 1b Study of KIO-301 in Retinitis Pigmentosa at The American Society of Neuroradiology 2023 Meeting
March 29, 2023
Kiora Pharmaceuticals Reports 2022 Financial Results; Provides Update on Clinical Development Progress
March 22, 2023
Kiora Pharmaceuticals Announces the Acceptance of Three Abstracts at the 2023 ARVO Annual Meeting
March 9, 2023
Kiora Pharmaceuticals Receives Investigational New Drug Approval for Phase 2 Study of KIO-101 for Treatment of Ocular Presentation of Autoimmune Diseases
February 6, 2023
Kiora Pharmaceuticals Completes Enrollment of Clinical Trial Evaluating KIO-201 for Persistent Corneal Epithelial Defects; Results Expected to be Reported in 1H 2023
January 2, 2023
Kiora Pharmaceuticals Enters Into Agreements to Raise $3.12 Million From the Exercise of Previously Issued Class A Warrants
November 17, 2022
Kiora Pharmaceuticals Doses First Patient in ABACUS Phase 1b Study Evaluating KIO-301 for Retinitis Pigmentosa
November 16, 2022
Kiora Pharmaceuticals Provides 3rd Quarter 2022 Business and Financial Update; Dosing of KIO-301 in Phase 1 Trial for Retinitis Pigmentosa to Begin Before Year's End
November 8, 2022
Kiora Pharmaceuticals Announces Publication of Phase 1 Trial Results for KIO-100 as a Treatment for Ocular Inflammatory Disease
October 16, 2022
Kiora Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements
October 12, 2022
Kiora Pharmaceuticals to Implement 1-for-40 Reverse Split
September 25, 2022
Kiora Pharmaceuticals Appoints Melissa Tosca as Executive Vice President of Finance
September 12, 2022
Kiora Pharmaceuticals Reports First Half 2022 Business Update and Financial Results
August 11, 2022
Kiora Pharmaceuticals Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
July 25, 2022
Kiora Pharmaceuticals Announces Pricing of $5.2 Million Underwritten Public Offering
July 21, 2022
Kiora Pharmaceuticals Announces First Patient Enrolled in Phase 2 Study Evaluating KIO-201 for Persistent Corneal Epithelial Defects
July 4, 2022
Kiora Pharmaceuticals Receives Clinical Trial Approval for First-in-Human Evaluation of KIO-301 to Restore Vision in Patients with Retinitis Pigmentosa
June 26, 2022
Kiora Pharmaceuticals Announces Presentation of KIO-101 Clinical Trial Data at the American Society of Cataract and Refractive Surgery 2022
April 24, 2022
Kiora Pharmaceuticals Reports 2021 Results and Provides Business Update
April 14, 2022
Kiora Pharmaceuticals Granted Orphan Drug Designation for KIO-301, an Investigational Drug for the Treatment of Retinitis Pigmentosa (RP)
March 17, 2022
Kiora Pharmaceuticals Announces Participation at 2022 BIO CEO & Investor Conference
February 7, 2022
Kiora Pharmaceuticals Appoints Erin Parsons to its Board of Directors; Stephen From to Retire from Board
January 31, 2022
Kiora Pharmaceuticals Appoints David Hollander, MD, MBA, to its Board of Directors
December 14, 2021
Kiora Reports KIO-101 is Safe and Tolerable; Topline Data Supports Advancing KIO-101 to a Phase 2 Study in Patients with Dry Eye Disease
December 13, 2021
Kiora Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update
November 14, 2021